Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MAPK8_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAPK8_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAPK8_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MAPK8_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAPK8_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAPK8_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAPK8_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAPK8_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAPK8_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAPK8_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
GO:000030210 | Cervix | CC | response to reactive oxygen species | 56/2311 | 222/18723 | 1.00e-07 | 5.25e-06 | 56 |
GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00075689 | Cervix | CC | aging | 75/2311 | 339/18723 | 2.75e-07 | 1.13e-05 | 75 |
GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
GO:00068399 | Cervix | CC | mitochondrial transport | 60/2311 | 254/18723 | 4.21e-07 | 1.67e-05 | 60 |
GO:00022379 | Cervix | CC | response to molecule of bacterial origin | 78/2311 | 363/18723 | 5.55e-07 | 2.06e-05 | 78 |
GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
GO:00324969 | Cervix | CC | response to lipopolysaccharide | 74/2311 | 343/18723 | 9.15e-07 | 3.25e-05 | 74 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:00514038 | Cervix | CC | stress-activated MAPK cascade | 55/2311 | 239/18723 | 2.96e-06 | 8.31e-05 | 55 |
GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
GO:00380933 | Cervix | CC | Fc receptor signaling pathway | 19/2311 | 50/18723 | 3.42e-06 | 9.17e-05 | 19 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513037 | Prostate | Tumor | Pathogenic Escherichia coli infection | 77/1791 | 197/8465 | 5.20e-09 | 7.77e-08 | 4.82e-08 | 77 |
hsa0541837 | Prostate | Tumor | Fluid shear stress and atherosclerosis | 58/1791 | 139/8465 | 2.70e-08 | 3.44e-07 | 2.13e-07 | 58 |
hsa0406832 | Prostate | Tumor | FoxO signaling pathway | 54/1791 | 131/8465 | 1.32e-07 | 1.51e-06 | 9.36e-07 | 54 |
hsa0516637 | Prostate | Tumor | Human T-cell leukemia virus 1 infection | 78/1791 | 222/8465 | 7.99e-07 | 8.02e-06 | 4.97e-06 | 78 |
hsa0516935 | Prostate | Tumor | Epstein-Barr virus infection | 72/1791 | 202/8465 | 1.15e-06 | 1.09e-05 | 6.73e-06 | 72 |
hsa0521035 | Prostate | Tumor | Colorectal cancer | 38/1791 | 86/8465 | 1.24e-06 | 1.14e-05 | 7.08e-06 | 38 |
hsa0501734 | Prostate | Tumor | Spinocerebellar ataxia | 54/1791 | 143/8465 | 3.50e-06 | 3.13e-05 | 1.94e-05 | 54 |
hsa0516736 | Prostate | Tumor | Kaposi sarcoma-associated herpesvirus infection | 67/1791 | 194/8465 | 9.21e-06 | 7.81e-05 | 4.85e-05 | 67 |
hsa0521232 | Prostate | Tumor | Pancreatic cancer | 33/1791 | 76/8465 | 9.72e-06 | 8.05e-05 | 4.99e-05 | 33 |
hsa0413736 | Prostate | Tumor | Mitophagy - animal | 30/1791 | 72/8465 | 6.31e-05 | 4.64e-04 | 2.88e-04 | 30 |
hsa0421035 | Prostate | Tumor | Apoptosis | 48/1791 | 136/8465 | 9.03e-05 | 6.10e-04 | 3.78e-04 | 48 |
hsa0513534 | Prostate | Tumor | Yersinia infection | 48/1791 | 137/8465 | 1.11e-04 | 7.25e-04 | 4.49e-04 | 48 |
hsa0472335 | Prostate | Tumor | Retrograde endocannabinoid signaling | 51/1791 | 148/8465 | 1.12e-04 | 7.25e-04 | 4.49e-04 | 51 |
hsa0152231 | Prostate | Tumor | Endocrine resistance | 37/1791 | 98/8465 | 1.17e-04 | 7.42e-04 | 4.60e-04 | 37 |
hsa0512033 | Prostate | Tumor | Epithelial cell signaling in Helicobacter pylori infection | 28/1791 | 70/8465 | 2.52e-04 | 1.43e-03 | 8.87e-04 | 28 |
hsa0514533 | Prostate | Tumor | Toxoplasmosis | 40/1791 | 112/8465 | 2.55e-04 | 1.43e-03 | 8.87e-04 | 40 |
hsa0466831 | Prostate | Tumor | TNF signaling pathway | 40/1791 | 114/8465 | 3.88e-04 | 2.07e-03 | 1.29e-03 | 40 |
hsa0401032 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
hsa0541737 | Prostate | Tumor | Lipid and atherosclerosis | 65/1791 | 215/8465 | 9.79e-04 | 4.44e-03 | 2.75e-03 | 65 |
hsa0491032 | Prostate | Tumor | Insulin signaling pathway | 44/1791 | 137/8465 | 1.69e-03 | 7.10e-03 | 4.40e-03 | 44 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | JNJ-7706621 | JNJ-7706621 | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | OXYTOCIN | OXYTOCIN | 11566737 |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | CYC-116 | CYC-116 | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | CI-1040 | CI-1040 | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | CHEMBL1950289 | TANZISERTIB | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | CENISERTIB | CENISERTIB | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | sorafenib | SORAFENIB | 20124951 |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565738 | | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 374883876 | | |
5599 | MAPK8 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME, TRANSCRIPTION FACTOR | | KEYHOLE LIMPET HEMOCYANIN | | 15857404 |